



EUROPEAN  
HEMATOLOGY  
ASSOCIATION



# Late effects of blood and marrow transplantation

Yoshihiro Inamoto<sup>1</sup> and Stephanie J. Lee<sup>2</sup>

<sup>1</sup>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan and <sup>2</sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

**Haematologica** 2017  
Volume 102(4):614-625

## ABSTRACT

**H**ematopoietic cell transplantation is a curative treatment for a variety of hematologic diseases. Advances in transplantation technology have reduced early transplant-related mortality and expanded application of transplantation to older patients and to a wider variety of diseases. Management of late effects after transplantation is increasingly important for a growing number of long-term survivors that is estimated to be half a million worldwide. Many studies have shown that transplant survivors suffer from significant late effects that adversely affect morbidity, mortality, working status and quality of life. Late effects include diseases of the cardiovascular, pulmonary, and endocrine systems, dysfunction of the thyroid gland, gonads, liver and kidneys, infertility, iron overload, bone diseases, infection, solid cancer, and neuropsychological effects. The leading causes of late mortality include recurrent malignancy, lung diseases, infection, secondary cancers and chronic graft-versus-host disease. The aim of this review is to facilitate better care of adult transplant survivors by summarizing accumulated evidence, new insights, and practical information about individual late effects. Further research is needed to understand the biology of late effects allowing better prevention and treatment strategies to be developed.

## Correspondence:

yinamoto@fredhutch.org

Received: November 24, 2016.

Accepted: January 20, 2017.

Pre-published: February 23, 2017.

doi:10.3324/haematol.2016.150250

Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: [www.haematologica.org/content/102/4/614](http://www.haematologica.org/content/102/4/614)

©2017 Ferrata Storti Foundation

Material published in *Haematologica* is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

<https://creativecommons.org/licenses/by-nc/4.0/legalcode>.

Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

<https://creativecommons.org/licenses/by-nc/4.0/legalcode>,

sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.



## Introduction

Hematopoietic cell transplantation (HCT) is a curative treatment for a variety of hematologic diseases.<sup>1</sup> The safety of HCT has improved over the decades,<sup>2</sup> indications for HCT have expanded to older patients,<sup>3</sup> and almost all patients are able to find suitable allogeneic donors by the growing use of cord blood<sup>4</sup> and haploidentical transplantation.<sup>5</sup> These current conditions have contributed to a growing number of HCT survivors, estimated to be half a million worldwide.<sup>6</sup>

Patients who are disease-free at two or five years after HCT have a greater than 80% subsequent 10-year survival rate,<sup>7-10</sup> but many studies show that HCT survivors suffer from significant late effects that adversely affect morbidity, mortality, working status and quality of life.<sup>7-15</sup> A prospective observational study of 1022 survivors who underwent HCT between 1974 and 1998 showed that 66% of the survivors had at least one chronic condition and 18% had severe or life-threatening conditions.<sup>14</sup> A retrospective study of 1087 contemporary survivors also showed that the cumulative incidence of any non-malignant late effect at five years after HCT was 45% among autologous and 79% among allogeneic recipients, and 2.5% of autologous and 26% of allogeneic recipients had three or more late effects.<sup>15</sup> Life expectancy among 5-year survivors remained 30% lower compared with the general population, regardless of their current ages and years since HCT.<sup>9</sup> The leading causes of excess deaths in 5-year survivors included secondary malignancies (27%) and recurrent disease (14%), followed by infections (12%), chronic graft-versus-host disease (GvHD) (11%), cardiovascular diseases (11%), and respiratory diseases (7%).<sup>9</sup>

The aim of this review is to facilitate better care of adult HCT survivors by summarizing accumulated evidence, new insights, and practical information about individual late effects (Figure 1). Recurrent disease and chronic GvHD are not discussed and readers are referred to other reviews.<sup>16-20</sup>

### Cardiovascular diseases

Cardiovascular diseases (CVD) after HCT include cardiomyopathy, congestive heart failure, valvular dysfunction, arrhythmia, pericarditis, and coronary artery disease.<sup>21</sup> Their cumulative incidences were 5%-10% at ten years after HCT,<sup>22-24</sup> accounting for 2%-11% of mortality among long-term survivors.<sup>8,9,25</sup> The incidence of CVD and its associated mortality were 1.4-3.5-fold higher compared with the general population.<sup>8,9,24,25</sup> HCT survivors are more likely to have conventional risk factors such as dyslipidemia and diabetes than the general population.<sup>26</sup> Early diagnosis and treatment of modifiable risk factors is important. We usually treat hypertension more than 140/90 mmHg on 2 separate visits or more than 130/80 mmHg for patients with diabetes or renal disease.<sup>27</sup> The first step is lifestyle modification including weight reduction, dietary sodium reduction and regular physical activity, followed by initiating antihypertensive drugs such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs).

Anthracycline exposure and chest radiation are the major risk factors for CVD after HCT.<sup>21</sup> Several studies showed that dexrazoxane, ACE inhibitors, ARBs and beta-blockers can prevent anthracycline-related cardiomyopathy in the non-HCT setting.<sup>28-32</sup> Once cardiomyopathy is established, it is important to initiate appropriate treatment. ACE inhibitors and beta-blockers have been effective in improving left ventricular function.<sup>33</sup>

### Pulmonary diseases

Non-infectious late complications of the lung include bronchiolitis obliterans syndrome (BOS), cryptogenic organizing pneumonia (COP) and pulmonary hypertension. BOS represents chronic GvHD of the lung, and is characterized by the new onset of fixed airflow obstruction after allogeneic HCT.<sup>34</sup> According to the strict 2005 National Institutes of Health (NIH) diagnostic criteria for chronic GvHD, incidence of BOS was 5.5% and its prevalence was 15% among patients with chronic GvHD.<sup>35</sup> Symptoms of BOS include dyspnea on exertion, cough and wheezing, but early BOS may be asymptomatic until significant lung function is lost.<sup>36</sup> One study showed rapid decline in %FEV1 during the six months before BOS diagnosis, with a lower %FEV1 at diagnosis associated with worse survival.<sup>37</sup> In our practice, we perform pulmonary function tests every three months including %FEV1 and FEV1/FVC among patients with active chronic GvHD. When testing shows significant new airflow obstruction, we repeat testing every month until stability is confirmed.<sup>38</sup> Plasma matrix metalloproteinase 3 levels<sup>39</sup> and parametric response mapping from CT scans<sup>40</sup> might be useful diagnostic tests for BOS but these have not yet entered clinical practice. Standard treatment of BOS is prednisone at 1 mg/kg per day, followed by a taper to reach a lower, alternate-day regimen.<sup>38</sup> A multicenter prospective study showed that addition of FAM (inhaled fluticasone propionate at 440 µg twice a day,




Figure 1. Late effects of blood and marrow transplantation.

azithromycin at 250 mg taken 3 days per week, and montelukast at 10 mg nightly) to prednisone treatment stabilized pulmonary function in 70% of patients with newly diagnosed BOS and permitted systemic steroid exposure to be reduced.<sup>41</sup>

Cryptogenic organizing pneumonia is a disorder involving bronchioles, alveolar ducts, and alveoli, the lumen of which become filled with buds of granulation tissue consisting of fibroblasts.<sup>42</sup> Clinical symptoms include dry cough, shortness of breath, and fever. Bronchoalveolar lavage is performed to exclude infection. Lung biopsy is required for definitive diagnosis, but an empiric diagnosis is often based on radiographic findings of diffuse, peripheral, fluffy infiltrates consistent with airspace consolidation. Pulmonary function testing shows restrictive changes and low diffusing capacity of the lungs for carbon monoxide. The incidence of COP is 2%-10%,<sup>43,44</sup> and it is strongly associated with acute and chronic GvHD.<sup>45</sup> COP usually responds within 5-7 days to prednisone at 1 mg/kg per day, which is continued for one month followed by a slow taper over five months because COP can often recur. Small case series suggest potential benefits of macrolides for treatment of COP.<sup>46</sup>

Pulmonary hypertension is an uncommon but potentially fatal complication after HCT, with a reported prevalence of 2.4%.<sup>47</sup> The most common symptoms are hypoxia, tachypnea, dyspnea, and acute respiratory failure,<sup>48</sup> and if untreated, pulmonary hypertension can result in a progressive increase in pulmonary vascular resistance, right ventricular failure and death. Since initial symptoms are non-specific, it is likely to be underdiagnosed after HCT. Although cardiac catheterization is the gold standard for diagnosis of pulmonary hypertension, high-resolution chest computed tomography and echocardiography are non-invasive and useful diagnostic modalities. The most common types are pulmonary arterial hypertension and pulmonary veno-occlusive disease, sometimes associated with transplant-associated microangiopathy and inherited or acquired hemolytic anemia.<sup>48</sup> First-line therapies are supplemental oxygen and phosphodiesterase-5 inhibitors, followed by inhaled nitric oxide, diuretics, bipyridine inotropes and after-load reducing agents.<sup>48</sup>

### Endocrine diseases

Major late effects in the endocrine system include thyroid dysfunction, diabetes, dyslipidemia, and adrenal insufficiency. Hypothyroidism occurs in 30% of patients by 25 years after HCT.<sup>49</sup> Risk factors include age under ten years, conditioning containing radiation, busulfan or cyclophosphamide, and hematologic malignancies.<sup>49,50</sup> The international guidelines recommend checking serum thyroid-stimulating hormone and free thyroxine levels every year.<sup>21</sup> For patients who received radiolabeled iodine antibody therapy, thyroid function should be checked earlier starting at three and six months after HCT, and other times as clinically indicated. Standard criteria are used to initiate replacement therapy for hypothyroidism. Some patients develop hyperthyroidism after HCT as a rare complication.<sup>51</sup>

Diabetes occurs in 8%-41% of patients after allogeneic HCT and in 3% of patients after autologous HCT.<sup>15,52,53</sup> Its incidence after allogeneic HCT is 3.65 times higher compared with their siblings.<sup>54</sup> Initial treatment is therapeutic lifestyle counseling, but many patients require hypoglycemic agents or insulin.

Dyslipidemia occurs in 9%-61% of HCT survivors.<sup>55,55</sup> Despite no established consensus for management of dyslipidemia after HCT, our practice is to initiate therapeutic lifestyle counseling followed by statin therapy when LDL cholesterol exceeds 130-190 mg/dL according to the estimated risk of CVD, based on the National Cholesterol Education Program Adult Treatment Panel III guidelines<sup>56</sup> and the recently suggested approach after allogeneic HCT.<sup>57</sup> The 2013 ACC/AHA guidelines do not specify the targeted levels for LDL cholesterol, and addition of statin therapy is based on calculated risk for future cardiovascular events.<sup>58</sup> Addition of omega-3-acid ethyl esters or fibrates is considered when fasting triglycerides exceed 200-499 mg/dL.

Adrenal insufficiency occurs in 13% of patients after allogeneic HCT and 1% of patients after autologous HCT,<sup>15</sup> and can be confirmed by a cortisol-stimulation test. Once adrenal insufficiency is diagnosed, physiological glucocorticoid replacement and a very slow terminal taper is needed. Patients should carry notification that they have adrenal insufficiency to alert emergency medical providers. For chronic GvHD therapy, the risk of adrenal insufficiency is lower with alternate-day administration of corticosteroids than with daily dosing,<sup>59</sup> although patients with brittle diabetes need daily dosing to allow for optimal glucose control.

### Male gonadal dysfunction and infertility

Hypogonadism is common after HCT. Impaired spermatogenesis, erectile dysfunction, low testosterone, and low libido occur in male patients. Erectile dysfunction and low libido have been associated with both physical and psychosocial factors.<sup>60,61</sup> Testosterone replacement may be considered for patients with low testosterone levels and has improved sexual function, libido and bone mass, although monitoring prostate-specific antigen and testosterone levels is necessary.<sup>62,63</sup> Azoospermia occurred in 70% of male patients, and spermatogenesis recovered in 90% of patients conditioned with cyclophosphamide alone, in 50% of patients conditioned with cyclophosphamide plus busulfan or thiotepa, and in 17% of patients conditioned with total body irradiation (TBI).<sup>64</sup> Semen banking or cryopreservation of testicular tissue should be discussed before HCT with patients desiring fertility.

### Female gonadal dysfunction, infertility and pregnancy

Ovarian insufficiency, vaginal changes and low libido occur in female patients. A historical study showed that ovarian failure occurred in more than 90% of female patients after HCT and recovered in 92% of patients conditioned with cyclophosphamide alone, but only in 24% of patients conditioned with cyclophosphamide and TBI.<sup>65</sup> A pilot study showed that only 10% of patients had ovarian failure after reduced-intensity allogeneic HCT.<sup>66</sup> The use of hormone replacement therapy for premature ovarian failure should be individualized based on the patient age, severity of menopausal symptoms, low bone density, risk of breast cancer, clotting predisposition and liver abnormalities.<sup>67</sup> Since efficacy of gonadotropin-releasing hormone agonists in preserving fertility in cancer patients is controversial,<sup>68,69</sup> cryopreservation of oocytes, ovarian tissue, or embryos should be discussed with patients desiring fertility.<sup>70</sup>

The largest study of pregnancy after HCT showed that

0.87% of patients or their partners had pregnancies after allogeneic HCT, and 0.36% of those after autologous HCT.<sup>71</sup> We generally recommend that women wait 2-5 years after HCT before attempting conception since rates of relapse are generally highest in the first two years after HCT. Another concern is the theoretical risk of recurrent malignancy because of disturbance of the graft-versus-leukemia effect, and some cases of recurrent chronic myeloid leukemia after conception have been reported.<sup>71</sup> Pregnancy outcomes are generally good with no increase in the risk of fetal malformations, although these pregnancies are considered high risk because of higher maternal risks of pregnancy complications.<sup>71</sup>

### Iron overload

Iron overload is rare after autologous HCT<sup>72</sup> but common after allogeneic HCT.<sup>73,74</sup> Previous prospective studies showed that 30%-60% of long-term survivors of allogeneic HCT had elevated serum ferritin levels and 25%-50% had elevated liver iron concentration on T2\* magnetic resonance imaging (MRI).<sup>73,74</sup> Since serum ferritin does not specifically reflect iron overload and can be elevated in hepatic and systemic inflammation, additional testing is required if the ferritin is elevated. We favor transferrin saturation, which is widely available and defined as the ratio of serum iron concentration divided by total iron-binding capacity.<sup>75</sup> Normal transferrin saturation is less than 50% in males and less than 45% in females. Patients with iron overload usually have saturation more than 60%. *HFE* genotyping is considered in patients with a family history of hemochromatosis and in patients of Northern or Western European ethnicity. When saturation is not elevated, other etiologies for an elevated ferritin including inflammation, metabolic syndrome, and alcoholism should be ruled out. The most accurate test of tissue iron concentration is liver biopsy, but the procedure is invasive and may cause serious complications. Thus, T2\* MRI and other modalities (FerriScan and superconducting quantum interference device) have been increasingly used.<sup>76</sup> Importantly, liver tests are often normal among long-term survivors with iron overload, so hepatitis and GvHD should also be considered when results of liver tests are elevated.<sup>77</sup> Iron overload may cause cardiomyopathy. Studies of thalassemia patients showed that cardiomyopathy typically took more than ten years to be clinically evident,<sup>78</sup> and that many patients improved with intensive chelation therapy.<sup>79</sup> Although a prospective study and a meta-analysis showed no statistical association of liver iron concentration with mortality after allogeneic HCT,<sup>80,81</sup> our practice is to start phlebotomy of 5 mL/kg or 250-300 mL every 3-4 weeks as long as hematocrit is more than 35% until serum ferritin falls below 1000 ng/mL. Deferasirox, an oral chelating agent, is considered for patients with anemia precluding phlebotomy.

### Liver diseases

Late liver diseases include chronic hepatitis B, chronic hepatitis C, liver cirrhosis, nodular regenerative hyperplasia and focal nodular hyperplasia.<sup>77</sup> Hepatitis B-infected patients have an increased risk of fulminant liver failure. One study reported a 35% risk of HBV reactivation after HCT even among patients with isolated anti-HBc antibodies, mostly during steroid treatment for GvHD.<sup>82</sup> Patients treated with anti-CD20 antibodies have an increased risk of HBV reactivation. Antiviral prophylaxis using entecavir

or lamivudine will prevent almost all fulminant cases if initiated before the start of conditioning regimens in patients with positive blood HBV DNA levels.<sup>83</sup> Patients with latent HBV (i.e. anti-HBc<sup>+</sup>/HBV DNA<sup>-</sup>) should be monitored monthly with HBV DNA levels after HCT and antiviral treatment should be initiated when viremia is detected.<sup>83</sup>

Hepatitis C virus infection in HCT survivors almost always results in chronic hepatitis.<sup>84,85</sup> Typically, asymptomatic elevation of alanine aminotransferase occurs 2-4 months after HCT, coinciding with tapering of immunosuppressive medications. There may be little liver-related mortality in the first ten years after HCT,<sup>84</sup> but liver cirrhosis occurs later with a cumulative incidence of 4%-24% at 20 years.<sup>85,86</sup> A large retrospective study showed that hepatitis C-infected patients had an increased risk of 2-year non-relapse mortality due to hepatic problems and bacterial infection.<sup>87</sup> Antiviral therapy for HCV has not been given early after HCT, but may improve both oncological and hepatic outcomes after HCT.<sup>88</sup> Ribavirin and interferon-based therapy have been used for patients who have discontinued all immunosuppressive medications without active GvHD, but it can cause pancytopenia and GvHD. Recently, highly effective and well tolerated direct acting antiviral agents with more than 90% rates of sustained virological response have been developed, and interferon-free regimens are now the treatments of choice.<sup>89,90</sup>

Nodular regenerative hyperplasia is a rare liver condition characterized by a widespread benign transformation of the hepatic parenchyma into small regenerative nodules.<sup>77</sup> This process is usually asymptomatic unless portal hypertension develops. Focal nodular hyperplasia occurs in 12% of HCT survivors, and possibly reflects sinusoidal injury caused by myeloablative conditioning regimens.<sup>91</sup>

### Kidney diseases

Chronic kidney disease (CKD) is defined as an elevated serum creatinine level, or a decreased glomerular filtration rate (GFR) less than 60 mL/min/1.73 m<sup>2</sup> for three months or longer.<sup>92</sup> CKD occurs in approximately 20% of HCT recipients.<sup>93-95</sup> There are three major etiologies of CKD after HCT: thrombotic microangiopathy (TMA), nephrotic syndrome and idiopathic CKD. Other etiologies include persistent acute kidney injury and BK virus nephropathy.<sup>96</sup> Whenever possible, renal biopsy should be considered to accurately diagnose the etiology of CKD and to provide appropriate management.<sup>97</sup>

Thrombotic microangiopathy occurs in 2%-21% of patients after HCT, and is characterized by renal dysfunction, thrombocytopenia, neurological dysfunction, hemolytic anemia with schistocytes, elevated lactate dehydrogenase and decreased haptoglobin.<sup>98,99</sup> Risk factors of TMA include TBI, calcineurin inhibitors, and acute and chronic GvHD.<sup>100-102</sup> TMA-related kidney injury often improves with tapering or stopping calcineurin inhibitors, but full renal function is rarely restored.<sup>103</sup> In some cases TMA did not improve until GvHD was treated.<sup>104</sup> Efficacy of plasma exchange is limited.<sup>105</sup>

Nephrotic syndrome occurs in 6%-8% of patients after allogeneic HCT.<sup>106,107</sup> Membranous nephropathy comprised 61% of cases, and minimal change disease comprised 22% of cases, with a median onset of 14 months and eight months after HCT, respectively.<sup>108</sup> Mechanisms of membranous nephropathy are thought to be formation of immune complexes through allo- or auto-antibodies

recognizing antigens expressed by the podocyte, while T cells are implicated with minimal change disease.<sup>109</sup> Nephrotic syndrome after HCT is often associated with chronic GvHD and tapering of immunosuppressive medications. Initial treatment is prednisone 1 mg/kg/day in addition to calcineurin inhibitors. Complete response was observed in 90% of patients with minimal change in disease, but only in 27% of patients with membranous nephropathy.<sup>108</sup> Refractory cases may be treated with rituximab or mycophenolate mofetil.<sup>110</sup>

Idiopathic CKD comprises most cases of CKD. Risk factors include acute GvHD, chronic GvHD, acute kidney injury, long-term use of calcineurin inhibitors and previous autologous HCT,<sup>94,111</sup> suggesting that GvHD, accompanying treatment and inflammatory conditions may have pathogenic roles in this entity. Associations of TBI with risk of CKD have been controversial.<sup>94,112</sup> ACE inhibitors and ARBs have been used to treat CKD and hypertension associated with CKD.<sup>113</sup>

### Bone diseases

Late complications of bone include osteopenia, osteoporosis and avascular necrosis (AVN).<sup>114</sup> Osteoporosis has been reported in as many as 50% of HCT recipients.<sup>115,116</sup> The diagnoses of osteopenia and osteoporosis are made by measuring T-scores with dual-energy X-ray absorptiometry. A T-score between -1.0 and -2.5 indicates osteopenia, and a T-score less than -2.5 or presence of a fragility fracture indicates osteoporosis.<sup>117</sup> Multiple risk factors are implicated including chemotherapy, radiation, corticosteroids, calcineurin inhibitors, vitamin D deficiency, and gonadal failure.<sup>116,118</sup> Bone loss occurs within 6-12 months after HCT, and recovery of bone mineral density (BMD) begins from the lumbar spine, followed by a slower recovery in the femoral neck. The use of corticosteroids is the strongest risk factor for osteoporosis. General preventative recommendations include adequate intake of calcium of 1200 mg per day or over and vitamin D of 1000 IU (25 µg) per day or over, regular weight-bearing exercise, and avoidance of smoking and excessive alcohol. Bisphosphonates are the primary treatment for bone loss.<sup>119</sup> Patients who are taking 5 mg or more daily prednisone-equivalent steroids for three months or more should have screening BMD tests for osteoporosis, and bisphosphonate treatment may be indicated until corticosteroid treatment is discontinued or for up to five years.<sup>120</sup> Second-line treatment includes calcitonin, raloxifene, denosumab, romosozumab, and blosozumab, though their reported use in HCT recipients is limited and adverse effects may be more prominent than with the bisphosphonates.

Avascular necrosis occurs in 4%-19% of HCT survivors with a cumulative incidence of 3%-10% at five years after HCT.<sup>121,122</sup> AVN causes severe bone pain and bone destruction, causing significant impairment in quality of life. AVN typically affects the femoral heads, but sometimes affects other joints such as the knee and shoulders.<sup>21</sup> Risk factors for AVN include corticosteroids, calcineurin inhibitors, older age and TBI conditioning.<sup>114</sup> When AVN is suspected, diagnostic MRI should be performed. Early involvement of an orthopedic specialist is important for management of AVN, including conservative treatment, joint-preserving surgery and joint replacement surgery.<sup>21,114</sup>

### Infectious diseases

All HCT survivors have some degree of immunodeficiency, particularly during the first year after HCT.<sup>123</sup> If patients

are able to stop immunosuppressive medications without GvHD or recurrent disease, many recover adequate immune function by one year after HCT. Patients with chronic GvHD, however, remain immunodeficient and have a high risk of infections. Common late infections are caused by *Pneumocystis jirovecii*, encapsulated bacteria, fungi, varicella-zoster virus (VZV), cytomegalovirus, and respiratory viruses. Patients may report more frequent episodes of upper respiratory infections and sinusitis.

All patients should receive prophylaxis against *Pneumocystis jirovecii* for at least one year after HCT or until 3-6 months after all immunosuppressive medication is discontinued, whichever occurs later. The preferred drug is trimethoprim-sulfamethoxazole, but dapsone or atovaquone could be substituted for patients who are allergic to or intolerant of trimethoprim-sulfamethoxazole.

In particular, patients with chronic GvHD are highly susceptible to encapsulated bacteria such as *Streptococcus pneumoniae*, *Haemophilus influenzae* and *Neisseria meningitidis* due to low levels of opsonizing antibodies, low CD4<sup>+</sup> T-cell counts, poor reticuloendothelial function and suppressive effects of immunosuppressive medications on phagocytosis. Vaccination against these bacteria is recommended.<sup>124</sup> Efficacy of vaccination in increasing antibody levels has been shown in several prospective studies.<sup>125,126</sup> Chemoprophylaxis is always recommended due to the unpredictable protection provided by vaccination. The first-line drug is trimethoprim-sulfamethoxazole, but if it is not tolerated, penicillin or azithromycin is substituted until 3-6 months after discontinuation of all immunosuppressive medications.

Invasive fungal infection occurs in 1% of patients after autologous HCT and in 6%-8% of patients after allogeneic HCT.<sup>127</sup> GvHD and long-term use of corticosteroids have been a major risk factor associated with onset of invasive fungal infection.<sup>128</sup> As recommended in the European guidelines, mold prophylaxis with posaconazole or voriconazole may be considered for patients with GvHD requiring high-dose corticosteroid treatment.<sup>129</sup>

Varicella-zoster virus-seropositive patients should receive prophylaxis with acyclovir or valacyclovir during the first year after HCT or until six months after discontinuation of immunosuppressive medications. A standard dose of acyclovir is 800 mg twice daily,<sup>130</sup> but some studies showed that 200 mg once daily was effective in preventing VZV reactivation.<sup>131</sup> Acyclovir should be started empirically if the patient presents with an acute abdomen or hepatitis typical of fulminant visceral VZV infection.<sup>132</sup> CMV monitoring in blood is continued beyond 100 days after HCT until one year for patients at risk of late CMV disease, including CMV-seropositive patients receiving high-dose corticosteroids, those who have already experienced CMV reactivation, and cord blood transplantation.<sup>133</sup> Pre-emptive therapy is usually considered for CMV levels of 250 IU/mL or more (equivalent to  $\geq 1000$  copies/mL) or a positive antigenemia test.

Community-acquired respiratory virus infections are an important cause of morbidity and mortality after HCT. The most frequent viruses include rhinovirus, respiratory syncytial virus (RSV), parainfluenza viruses (PIV), human metapneumovirus, and influenza viruses as these frequently cause lower respiratory tract disease associated with 12%-100% mortality.<sup>134</sup> An immunodeficiency scoring index can predict severity of RSV infection.<sup>135</sup> Aerosolized ribavirin showed efficacy in treating lower tract RSV after HCT.<sup>136</sup>

Combination therapy with immunomodulators such as intravenous immunoglobulin or palivizumab has been seen to have variable success.<sup>137</sup> Treatment for PIV infection has not been established. Efficacy of ribavirin has been limited for patients with lower respiratory tract infection of PIV.<sup>138</sup> Novel drugs such as a recombinant sialidase fusion protein and a hemagglutinin-neuraminidase inhibitor are under investigation.<sup>138</sup>

### Solid cancers

There is an increased risk of solid cancers following both autologous and allogeneic HCT compared with the general population. The cumulative incidence is 1%-6% at ten years after HCT, and continues to rise over time without a plateau.<sup>139-142</sup> The most common sites include oral cavity, skin, breast and thyroid, but rates are also elevated in esophagus, liver, nervous system, bone and connective tissues compared with the general population.<sup>143</sup> Myeloablative TBI, young age at HCT, chronic GvHD and prolonged immunosuppressive medications beyond two years are well-documented risk factors for many types of cancers.<sup>143</sup> All HCT recipients should be advised of the risk of second cancers and should be encouraged to undergo recommended screening tests based on their predisposition.<sup>143</sup> The 5-year overall survival rates after diagnosis of solid cancers varied by cancer site, with

88%-100% for thyroid, testis and melanoma, approximately 50% for breast, mouth, soft tissue and female reproductive organs, and 20% or less for bone, lower gastrointestinal tract, and central nervous system.<sup>144</sup> These rates were similar to those of *de novo* cancers, except that rates were lower for female reproductive organs, bone, colorectum, and central nervous system, although further studies are warranted to confirm this observation. There is emerging evidence that human papilloma virus (HPV) is involved in the pathogenesis of squamous cell cancer after HCT.<sup>145,146</sup> The efficacy of HPV vaccination in preventing squamous cell cancer after HCT remains to be determined in prospective studies.<sup>147</sup>

### Neuropsychological effects

Neuropsychological effects after HCT are being increasingly recognized and include, among others, depression, post-traumatic stress disorder, and neurocognitive deficits. Depression occurs in 12%-30% of HCT survivors and is more frequent in female patients, younger patients and those with poor social support, history of recurrent disease, chronic pain, and chronic GvHD.<sup>148</sup> Post-traumatic stress disorder occurs in 28% of patients at six months after HCT and may persist for 5%-13% of cases, although its risk factors are not yet clear.<sup>148-150</sup>

Neurocognitive deficits, so called "chemo brain", have

**Table 1.** Late effects after blood and marrow transplantation

Late effect	Incidence	Mortality	Morbidity	Treatable	Preventable
Cardiovascular	+	+	+	+	+
Pulmonary					
Bronchiolitis obliterans syndrome	+	++	++	+	-
Cryptogenic organizing pneumonia	+	+	+	++	-
Pulmonary hypertension	+	++	++	+	-
Endocrine					
Thyroid dysfunction	++	-	-/+	+++	-
Diabetes	++	+	+	+++	-
Dyslipidemia	++	-	-/+	+++	-
Adrenal insufficiency	+	-	-/+	+++	-/+
Gonadal dysfunction/infertility	+++	-	-	-/+	-/+
Iron overload	++	-	-	++	-
Liver					
Hepatitis B	+	-	+	++	+
Hepatitis C and cirrhosis	+	-	+	++	-/+
Nodular regenerative hyperplasia	+	-	-	-	-
Focal nodular hyperplasia	+	-	-	-	-
Kidney					
Thrombotic microangiopathy	+	+	++	-/+	-
Nephrotic syndrome	+	-	++	++	-
Idiopathic chronic kidney disease	+	-	++	+	-
Bone					
Osteoporosis/osteopenia	++	-	-	++	+
Avascular necrosis	+	-	++	++	-
Infection	++	+	+	+++	+
Solid cancer	+	++	+++	-/+	-
Neuropsychological	++	-	++	+	-
Recurrent disease	++	+++	+++	-/+	-
Chronic graft-versus-host disease	++	+	++	+	-

+ : <20%; ++ : 20%-50%; +++ : >50%.

**Table 2.** Tests, preventive approaches and treatment of late effects.

Late effect	Tests	Preventive approaches	Treatment
<b>Cardiovascular</b>			
Anthracycline-related cardiomyopathy	Physical exam, chest X-ray, electrocardiogram, echocardiogram, brain natriuretic peptide level	Dexrazoxane, ACE inhibitors, ARBs, beta-blockers	ACE inhibitors, ARBs, beta-blockers
Others	Blood pressure, lipid panel, glucose level, HbA1c, glycoalbumin	Lifestyle modification, ACE inhibitors, ARBs	
<b>Pulmonary</b>			
Bronchiolitis obliterans syndrome	%FEV1, FEV1/FVC	Prednisone, FAM	
Cryptogenic organizing pneumonia	CT, lung biopsy	Prednisone, macrolides	
Pulmonary hypertension	High-resolution chest CT, echocardiography, cardiac catheterization		Oxygen, phosphodiesterase-5 inhibitors, inhaled nitric oxide, diuretics, bipyridine inotropes, after-load reducing agents
<b>Endocrine</b>			
Hypothyroidism	Thyroid-stimulating hormone, thyroxine levels		Replacement therapy
Diabetes	Glucose level, HbA1c, glycoalbumin		Lifestyle modification, hyperglycemic agents, insulin
Dyslipidemia	Lipid panel		Lifestyle modification, statins, fibrates, fish oil (omega-3 fatty acids), ezetimibe
Adrenal insufficiency	Cortisol-stimulation test	Alternate-day regimen when corticosteroids are used	Hydrocortisone, low-dose prednisone
<b>Gonadal dysfunction</b>			
Male patients	Testosterone level		Testosterone replacement
Female patients	Follicle-stimulating hormone, lutenizing hormone, estradiol levels	Reduced-intensity conditioning	Hormone replacement
Infertility	Sperm test	Semen banking, cryopreservation of testicular or ovarian tissues	Assisted reproduction, surrogate pregnancy, adoption
Iron overload	Serum ferritin levels, transferrin saturation, Prussian blue-stained marrow biopsy, T2* MRI, FerriScan, SQUID		Phlebotomy, desferoxamine, deferasirox
<b>Liver</b>			
Hepatitis B	ALT, HBV DNA levels	Entecavir, lamivudine	Entecavir, lamivudine
Hepatitis C and cirrhosis	ALT, HCV RNA levels	Direct acting antiviral agents	Direct acting antiviral agents, interferon

*continued in the next page*

adverse functional impacts on HCT survivors who return to work and daily activities that require short-term memory, information-processing speed, multitasking and co-ordination.<sup>151</sup> Neuropsychological tests can help identify neurocognitive deficits. Most evidence is derived from studies of breast cancer survivors, with estimated rates of deficits ranging from 16% to 50% up to ten years after treatment.<sup>152,153</sup> Potential mechanisms for chemotherapy-induced neurocognitive changes include cytokine and immune dysregulation, damage to DNA and telomere length through cytotoxic agents, oxidative stress and hormonal changes.<sup>154</sup> In cases of HCT survivors, there may be additional deficits derived from neurological complications including nervous system infection (HHV-6, fungi, etc.), immune-mediated damage, and toxicities of calcineurin inhibitors such as TMA and posterior reversible encephalopathy syndrome. A prospective observational study showed that neurocognitive function declined substantially at 80 days after HCT, returned to pre-transplantation levels at one year, and continued to improve between one and five years after HCT, except for motor dexterity and verbal learning and retention.<sup>155</sup> Mostly mild, neurocognitive dysfunction according to the Global Deficit Score persisted at five years in 42% of

long-term survivors.<sup>155</sup> Rehabilitation programs have succeeded in improving neurocognitive functions,<sup>156</sup> and methylphenidate and modafinil have demonstrated variable efficacies to improve neurocognitive function in non-HCT cancer patients.<sup>157,158</sup> Efficacies of these interventions remain to be determined among HCT survivors.

### Influence of newer practices on late effects

An understanding of the influence of newer practices such as cord blood transplantation, non-TBI or reduced-intensity conditioning regimens and older patients on the incidence and severity of late effects awaits longer follow up. For example, TBI is associated with an increased risk of many late effects such as cardiovascular diseases, COP, hypothyroidism, diabetes, dyslipidemia, infertility, TMA-related kidney injury, bone density loss, avascular necrosis, and secondary solid cancer.<sup>49,54,100,102,114,118,143,159,160</sup> The use of non-TBI conditioning regimens might reduce the burden of these late effects among HCT survivors. Some studies found that cumulative incidences of late effects did not differ much after reduced-intensity regimens compared with myeloablative regimens,<sup>15,161</sup> and reduced-intensity conditioning was associated with a higher risk of recurrent malignancy.

continued from the previous page

Late effect	Tests	Preventive approaches	Treatment
<b>Kidney</b>			
Thrombotic microangiopathy	CBC, schistocytes, serum creatinine, lactate dehydrogenase, haptoglobin, renal biopsy		Taper or stop calcineurin inhibitors, GvHD treatment required in some cases
Nephrotic syndrome	Urine protein, renal biopsy		Prednisone, rituximab, mycophenolate mofetil, ACE inhibitors, ARBs
Idiopathic chronic kidney disease	Renal biopsy		
<b>Bone</b>			
Osteoporosis/osteopenia	Dual-energy X-ray absorptiometry	Calcium intake, vitamin D intake, bisphosphonate, estrogen, testosterone	Bisphosphonate, estrogen, testosterone, (calcitonin, raloxifene, denosumab, romosozumab, blosozumab)
Avascular necrosis	MRI		Conservative treatment, surgery
<b>Infection</b>			
<i>Pneumocystis jirovecii</i>	Bronchoalveolar lavage, PCR, $\beta$ -D-glucan	Trimethoprim-sulfamethoxazole, dapsone, atovaquone	Prednisone, trimethoprim-sulfamethoxazole, atovaquone, pentamidine
Encapsulated bacteria		Trimethoprim-sulfamethoxazole, penicillin, azithromycin, vaccination against <i>Haemophilus influenzae</i> type b, <i>Neisseria meningitidis</i> , <i>Streptococcus pneumoniae</i>	Antibiotics
Fungi	Galactomannan assay, $\beta$ -D-glucan, CT	Posaconazole, voriconazole	Antifungal agents
Varicella-zoster virus	PCR	Acyclovir, valacyclovir	Acyclovir, valacyclovir
Cytomegalovirus	PCR, antigenemia	Ganciclovir, valganciclovir, foscarnet	Ganciclovir, valganciclovir, foscarnet
Respiratory syncytial virus	PCR	Aerosolized ribavirin, palivizumab	
Influenza virus	Immunoassay	Vaccination	Oseltamivir
<b>Solid cancer</b>	Recommended screening tests (see reference <sup>145</sup> )	(Human papillomavirus vaccination)	Site- and stage-specific treatment
<b>Neuropsychological</b>	Neuropsychological test, MRI		Rehabilitation, methylphenidate, modafinil

ACE: angiotension-converting enzyme; ARBs: angiotensin II receptor blockers; FAM: inhaled fluticasone propionate, azithromycin and montelukast; CT: computed tomography; MRI: magnetic resonance imaging; SQUID: superconducting quantum interference device; ALT: alanine aminotransferase; GvHD: graft-versus-host disease; PCR: polymerase chain reaction.

nancy among patients with myeloid malignancy.<sup>162</sup> One study showed that the risk of AVN was elevated after cord blood transplantation, but graft source had a limited influence on other long-term health status and QOL.<sup>163</sup>

### Consensus guidelines for late effects and prevention behaviors

Incidence, mortality, morbidity and management of individual late effects are summarized in Tables 1 and 2. Recognizing the importance of managing late effects after HCT, the Center for International Blood and Marrow Transplant Research (CIBMTR), the European Group for Blood and Marrow Transplantation (EBMT), and the American Society for Bone Marrow Transplantation (ASBMT) developed recommendations in 2006 for screening and prevention practices for HCT survivors.<sup>164</sup> Consensus recommendations were up-dated in 2011 including other international transplant communities.<sup>21</sup> The NIH convened working groups to formulate late effects initiatives in 2015.<sup>148,165-169</sup>

Despite higher levels of engagement with health care providers, HCT survivors had similar health and prevention behaviors as matched untransplanted controls, suggesting the need for further education of both HCT survivors and health practitioners.<sup>170</sup> Major modifiable predictors of lower

adherence to preventive care practices were concerns about medical costs and lack of knowledge.<sup>171</sup>

### Conclusion

While the number of HCT survivors is growing, there is no evidence that the burden of late effects is lessening. HCT survivors face myriad late effects that can limit their functioning, require prolonged or life-long medical treatment, reduce their quality of life and also shorten their survival. To the extent that the HCT procedure itself causes these late effects, the transplant community has a responsibility to appropriately monitor, treat and ultimately try to prevent late effects. Given the dispersion of survivors and the varied structure of health care, hematologists, oncologists, primary care physicians and medical subspecialists are all involved in providing this care. Further research is needed to understand the biology of late effects to help identify better prevention and treatment strategies.<sup>166</sup>

### Funding

This work was supported by grants from the Japan Society for the Promotion of Science (15K19563), from the Friends of Leukemia Research Fund, and from the National Institutes of Health (CA18953 and CA18029).

## References

1. Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation (first of two parts). *N Engl J Med.* 1975;292(16):832-843.
2. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. *N Engl J Med.* 2010;363(22):2091-2101.
3. Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. *JAMA.* 2011;306(17):1874-1883.
4. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. *N Engl J Med.* 1997;337(6):373-381.
5. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. *Biol Blood Marrow Transplant.* 2008;14(6):641-650.
6. Gratwohl A, Pasquini MC, Aljurf M, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. *Lancet Haematol.* 2015;2(3):e91-100.
7. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. *N Engl J Med.* 1999;341(1):14-21.
8. Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. *Blood.* 2005;105(11):4215-4222.
9. Martin PJ, Counts GW Jr, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. *J Clin Oncol.* 2010;28(6):1011-1016.
10. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. *J Clin Oncol.* 2011;29(16):2230-2239.
11. Duell T, van Lint MT, Ljungman P, et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. *Ann Intern Med.* 1997;126(3):184-192.
12. Chiodi S, Spinelli S, Ravera G, et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation. *Br J Haematol.* 2000;110(3):614-619.
13. Lee SJ, Logan B, Westervelt P, et al. Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial. *JAMA Oncol.* 2016;2(12):1583-1589.
14. Sun CL, Francisco L, Kawashima T, et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. *Blood.* 2010;116(17):3129-3139.
15. Khera N, Storer B, Flowers ME, et al. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. *J Clin Oncol.* 2012;30(1):71-77.
16. Avigan D, Hari P, Battiwalla M, et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies. *Biol Blood Marrow Transplant.* 2013;19(12):1661-1669.
17. Gress RE, Miller JS, Battiwalla M, et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation. *Biol Blood Marrow Transplant.* 2013;19(11):1537-1545.
18. de Lima M, Porter DL, Battiwalla M, et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. *Biol Blood Marrow Transplant.* 2014;20(1):4-13.
19. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. *Biol Blood Marrow Transplant.* 2015;21(3):389-401.
20. Carpenter PA, Kitko CL, Elad S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. *Biol Blood Marrow Transplant.* 2015;21(7):1167-1187.
21. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2012;18(3):348-371.
22. Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. *Blood.* 2007;110(9):3463-3471.
23. Tichelli A, Passweg J, Wojcik D, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica.* 2008;93(8):1203-1210.
24. Chow EJ, Mueller BA, Baker KS, et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. *Ann Intern Med.* 2011;155(1):21-32.
25. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. *Blood.* 2007;110(10):3784-3792.
26. Chow EJ, Baker KS, Lee SJ, et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. *J Clin Oncol.* 2014;32(3):191-198.
27. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA.* 2014;311(5):507-520.
28. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. *Lancet Oncol.* 2010;11(10):950-961.
29. Chow EJ, Asselin BL, Schwartz CL, et al. Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group. *J Clin Oncol.* 2015;33(24):2639-2645.
30. Asselin BL, Devidas M, Chen L, et al. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. *J Clin Oncol.* 2016;34(8):854-862.
31. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. *Circulation.* 2006;114(23):2474-2481.
32. Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. *Am J Hematol.* 2010;85(11):894-896.
33. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. *J Am Coll Cardiol.* 2010;55(3):213-220.
34. Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. *Biol Blood Marrow Transplant.* 2010;16(1 Suppl):S106-114.
35. Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2011;17(7):1072-1078.
36. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. *Biol Blood Marrow Transplant.* 2003;9(10):657-666.
37. Cheng GS, Storer B, Chien JW, et al. Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. *Ann Am Thorac Soc.* 2016;13(11):1932-1939.
38. Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. *Blood.* 2015;125(4):606-615.
39. Liu X, Yue Z, Yu J, et al. Proteomic Characterization Reveals That MMP-3 Correlates With Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell and Lung Transplantation. *Am J Transplant.* 2016;16(8):2342-2351.
40. Galban CJ, Boes JL, Bule M, et al. Parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2014;20(10):1592-1598.
41. Williams KM, Cheng GS, Pusic I, et al.

- Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant.* 2016;22(4):710-716.
42. Epler GR, Colby TV, McLoud TC, Carrington CB, Gaensler EA. Bronchiolitis obliterans organizing pneumonia. *N Engl J Med.* 1985;312(3):152-158.
  43. Palmas A, Tefferi A, Myers JL, et al. Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation. *Br J Haematol.* 1998;100(4):680-687.
  44. Patriarca F, Skert C, Sperotto A, et al. Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation. *Bone Marrow Transplant.* 2004;33(7):751-758.
  45. Freudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. *Blood.* 2003;102(10):3822-3828.
  46. Pathak V, Kuhn JM, Durham C, Funkhouser WK, Henke DC. Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia. *Ann Am Thorac Soc.* 2014;11(1):87-91.
  47. Jodele S, Hirsch R, Laskin B, Davies S, Witte D, Chima R. Pulmonary arterial hypertension in pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy. *Biol Blood Marrow Transplant.* 2013;19(2):202-207.
  48. Dandoy CE, Hirsch R, Chima R, Davies SM, Jodele S. Pulmonary hypertension after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2013;19(11):1546-1556.
  49. Sanders JE, Hoffmeister PA, Woolfrey AE, et al. Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. *Blood.* 2009;113(2):306-308.
  50. Berger C, Le-Gallo B, Donadieu J, et al. Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. *Bone Marrow Transplant.* 2005;35(10):991-995.
  51. Aldouri MA, Ruggier R, Epstein O, Prentice HG. Adoptive transfer of hyperthyroidism and autoimmune thyroiditis following allogeneic bone marrow transplantation for chronic myeloid leukaemia. *Br J Haematol.* 1990;74(1):118-119.
  52. Majhail NS, Flowers ME, Ness KK, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant.* 2009;43(1):49-54.
  53. Abou-Mourad YR, Lau BC, Barnett MJ, et al. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. *Bone Marrow Transplant.* 2010;45(2):295-302.
  54. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. *Blood.* 2007;109(4):1765-1772.
  55. Rovo A, Daikeler T, Halter J, et al. Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor. *Haematologica.* 2011;96(1):150-155.
  56. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation.* 2002;106(25):3143-3421.
  57. Griffith ML, Savani BN, Boord JB. Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. *Blood.* 2010;116(8):1197-1204.
  58. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2014;63(25 Pt B):2889-2934.
  59. Ackerman GL, Nolsn CM. Adrenocortical responsiveness after alternate-day corticosteroid therapy. *N Engl J Med.* 1968;278(8):405-409.
  60. Molassiotis A, van den Akker OB, Milligan BW, Boughton BJ. Gonadal function and psychosexual adjustment in male long-term survivors of bone marrow transplantation. *Bone Marrow Transplant.* 1995;16(2):253-259.
  61. Chatterjee R, Andrews HO, McGarrigle HH, et al. Cavernosal arterial insufficiency is a major component of erectile dysfunction in some recipients of high-dose chemotherapy/chemo-radiotherapy for haematological malignancies. *Bone Marrow Transplant.* 2000;25(11):1185-1189.
  62. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. *J Clin Endocrinol Metab.* 1997;82(8):2386-2390.
  63. Chatterjee R, Kottaridis PD, McGarrigle HH, Linch DC. Management of erectile dysfunction by combination therapy with testosterone and sildenafil in recipients of high-dose therapy for haematological malignancies. *Bone Marrow Transplant.* 2002;29(7):607-610.
  64. Anserini P, Chiodi S, Spinelli S, et al. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. *Bone Marrow Transplant.* 2002;30(7):447-451.
  65. Sanders JE, Buckner CD, Amos D, et al. Ovarian function following marrow transplantation for aplastic anemia or leukemia. *J Clin Oncol.* 1988;6(5):813-818.
  66. Phelan R, Mann E, Napurski C, et al. Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning. *Bone Marrow Transplant.* 2016;51(10):1369-1375.
  67. Fish JD. Part 1: Hormone replacement for survivors of childhood cancer with ovarian failure--when is it worth the risk? *J Pediatr Adolesc Gynecol.* 2011;24(2):98-101.
  68. Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. *J Clin Oncol.* 2012;30(5):533-538.
  69. Demeestere I, Brice P, Peccatori FA, et al. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. *J Clin Oncol.* 2016;34(22):2568-2574.
  70. Joshi S, Savani BN, Chow EJ, et al. Clinical guide to fertility preservation in hematopoietic cell transplant recipients. *Bone Marrow Transplant.* 2014;49(4):477-484.
  71. Salooja N, Szydlo RM, Socie G, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. *Lancet.* 2001;358(9278):271-276.
  72. Majhail NS, DeFor TE, Lazarus HM, Burns LJ. Iron-overload after autologous hematopoietic cell transplantation. *Leuk Res.* 2009;33(4):578-579.
  73. Rose C, Ernst O, Hecquet B, et al. Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long term survivors after allogeneic hematopoietic stem cell transplantation (HSCT). *Haematologica.* 2007;92(6):850-853.
  74. Majhail NS, Lazarus HM, Burns LJ. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. *Biol Blood Marrow Transplant.* 2010;16(6):832-837.
  75. Schrier SL, Bacon BR. Approach to the patient with suspected iron overload. In: *UpToDate, Post TW (Ed.), UpToDate, Waltham, MA.* Accessed on December 30, 2016.
  76. Au WY, Lam WM, Chu WC, et al. A magnetic resonance imaging study of iron overload in hemopoietic stem cell transplant recipients with increased ferritin levels. *Transplant Proc.* 2007;39(10):3369-3374.
  77. McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. *Hepatology.* 2010;51(4):1450-1460.
  78. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. *Blood.* 1997;89(3):739-761.
  79. Aldouri MA, Wonke B, Hoffbrand AV, et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. *Acta Haematol.* 1990;84(3):113-117.
  80. Trotter BJ, Burns LJ, DeFor TE, Cooley S, Majhail NS. Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. *Blood.* 2013;122(9):1678-1684.
  81. Armand P, Kim HT, Virtanen JM, et al. Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. *Biol Blood Marrow Transplant.* 2014;20(8):1248-1251.
  82. Picardi M, De Rosa G, Sella C, Pane F, Rotoli B, Muretto P. Clinical relevance of intrahepatic hepatitis B virus DNA in HBsAg-negative HBcAb-positive patients undergoing hematopoietic stem cell transplantation for hematological malignancies. *Transplantation.* 2006;82(1):141-142.
  83. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. *Blood.* 2009;113(14):3147-3153.
  84. Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. *Hepatology.* 1999;29(6):1893-1899.

85. Peffault de Latour R, Levy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. *Blood*. 2004;103(5):1618-1624.
86. Strasser SI, Sullivan KM, Myerson D, et al. Cirrhosis of the liver in long-term marrow transplant survivors. *Blood*. 1999;93(10):3259-3266.
87. Nakasone H, Kurosawa S, Yakushijin K, et al. Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation. *Am J Hematol*. 2013;88(6):477-484.
88. Kyvernitakis A, Mahale P, Popat UR, et al. Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents. *Biol Blood Marrow Transplant*. 2016;22(4):717-722.
89. Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. *Hepatology*. 2015;62(3):932-954.
90. Torres HA, McDonald GB. How I treat hepatitis C virus infection in patients with hematologic malignancies. *Blood*. 2016;128(11):1449-1457.
91. Sudour H, Mainard L, Baumann C, Clement L, Salmon A, Bordigoni P. Focal nodular hyperplasia of the liver following hematopoietic SCT. *Bone Marrow Transplant*. 2009;43(2):127-132.
92. National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis*. 2002;39(2 Suppl 1):S1-266.
93. Choi M, Sun CL, Kurian S, et al. Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation. *Cancer*. 2008;113(7):1580-1587.
94. Hingorani S, Guthrie KA, Schoch G, Weiss NS, McDonald GB. Chronic kidney disease in long-term survivors of hematopoietic cell transplant. *Bone Marrow Transplant*. 2007;39(4):223-229.
95. Hingorani S. Renal Complications of Hematopoietic-Cell Transplantation. *N Engl J Med*. 2016;374(23):2256-2267.
96. Verghese PS, Finn LS, Englund JA, Sanders JE, Hingorani SR. BK nephropathy in pediatric hematopoietic stem cell transplant recipients. *Pediatr Transplant*. 2009;13(7):913-918.
97. Chang A, Hingorani S, Kowalewska J, et al. Spectrum of renal pathology in hematopoietic cell transplantation: a series of 20 patients and review of the literature. *Clin J Am Soc Nephrol*. 2007;2(5):1014-1023.
98. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2005;11(8):571-575.
99. Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. *Haematologica*. 2007;92(1):95-100.
100. Cohen EP, Lawton CA, Moulder JE. Bone marrow transplant nephropathy: radiation nephritis revisited. *Nephron*. 1995;70(2):217-222.
101. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. *Bone Marrow Transplant*. 1994;14(4):495-504.
102. Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. *Br J Haematol*. 2001;113(1):58-64.
103. Abboud I, Peraldi MN, Hingorani S. Chronic kidney diseases in long-term survivors after allogeneic hematopoietic stem cell transplantation: monitoring and management guidelines. *Semin Hematol*. 2012;49(1):73-82.
104. Oran B, Donato M, Aleman A, et al. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. *Biol Blood Marrow Transplant*. 2007;13(4):469-477.
105. Christidou F, Athanasiadou A, Kalogiannidis P, et al. Therapeutic plasma exchange in patients with grade 2-3 hematopoietic stem cell transplantation-associated thrombotic thrombocytopenic purpura: a ten-year experience. *Ther Apher Dial*. 2003;7(2):259-262.
106. Srinivasan R, Balow JE, Sabnis S, et al. Nephrotic syndrome: an under-recognized immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. *Br J Haematol*. 2005;131(1):74-79.
107. Colombo AA, Rusconi C, Esposito C, et al. Nephrotic syndrome after allogeneic hematopoietic stem cell transplantation as a late complication of chronic graft-versus-host disease. *Transplantation*. 2006;81(8):1087-1092.
108. Brukamp K, Doyle AM, Bloom RD, Bunin N, Tomaszewski JE, Cizman B. Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease? *Clin J Am Soc Nephrol*. 2006;1(4):685-694.
109. Rao PS. Nephrotic syndrome in patients with peripheral blood stem cell transplant. *Am J Kidney Dis*. 2005;45(4):780-785.
110. Terrier B, Delmas Y, Hummel A, et al. Post-allogeneic haematopoietic stem cell transplantation membranous nephropathy: clinical presentation, outcome and pathogenic aspects. *Nephrol Dial Transplant*. 2007;22(5):1369-1376.
111. Weiss AS, Sandmaier BM, Storer B, Storb R, McSweeney PA, Parikh CR. Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. *Am J Transplant*. 2006;6(1):89-94.
112. Miralbell R, Bieri S, Mermillod B, et al. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. *J Clin Oncol*. 1996;14(2):579-585.
113. Cohen EP, Irving AA, Drobyski WR, et al. Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. *Int J Radiat Oncol Biol Phys*. 2008;70(5):1546-1551.
114. McClune B, Majhail NS, Flowers ME. Bone loss and avascular necrosis of bone after hematopoietic cell transplantation. *Semin Hematol*. 2012;49(1):59-65.
115. Yao S, McCarthy PL, Dunford LM, et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. *Bone Marrow Transplant*. 2008;41(4):393-398.
116. Savani BN, Donohue T, Kozanas E, et al. Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. *Biol Blood Marrow Transplant*. 2007;13(5):517-520.
117. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. *Osteoporos Int*. 1994;4(6):368-381.
118. Stern JM, Sullivan KM, Ott SM, et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. *Biol Blood Marrow Transplant*. 2001;7(5):257-264.
119. Tauchmanova L, Selleri C, Esposito M, et al. Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. *Osteoporos Int*. 2003;14(12):1013-1019.
120. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. *Arthritis Rheuma*. 2001;44(7):1496-1503.
121. Enright H, Haake R, Weisdorf D. Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation. *Ma J Med*. 1990;89(6):733-738.
122. Socie G, Cahn JY, Carmelo J, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Societe Francaise de Greffe de Moelle (SFGM). *Br J Haematol*. 1997;97(4):865-870.
123. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. *Biol Blood Marrow Transplant*. 2009;15(10):1143-1238.
124. Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. *Blood*. 2016;127(23):2824-2832.
125. Cordonnier C, Ljungman P, Juergens C, et al. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged  $\geq 2$  years: an open-label study. *Clin Infect Dis*. 2015;61(3):313-323.
126. Patel SR, Ortin M, Cohen BJ, et al. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. *Clin Infect Dis*. 2007;44(5):625-634.
127. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. *Clin Infect Dis*. 2010;50(8):1091-1100.
128. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. *Blood*. 2002;100(13):4358-4366.
129. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. *Bone Marrow Transplant*. 2011;46(5):709-718.
130. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study. *Blood*. 2006;107(5):1800-1805.
131. Asano-Mori Y, Kanda Y, Oshima K, et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplanta-

- tion. *Am J Hematol.* 2008;83(6):472-476.
132. David DS, Tegtmeier BR, O'Donnell MR, Paz IB, McCarty TM. Visceral varicella-zoster after bone marrow transplantation: report of a case series and review of the literature. *Am J Gastroenterol.* 1998;93(5):810-813.
  133. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. *Blood.* 2003;101(2):407-414.
  134. Forman SJ, Negrin RS, Antin JH, Appelbaum FR. *Thomas' Hematopoietic Cell Transplantation*, 5th Edition. Oxford, UK: Wiley-Blackwell, 2015.
  135. Shah DP, Ghantaji SS, Ariza-Heredia EJ, et al. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. *Blood.* 2014;123(21):3263-3268.
  136. Boeckh M, Englund J, Li Y, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. *Clin Infect Dis.* 2007;44(2):245-249.
  137. de Fontbrune FS, Robin M, Porcher R, et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. *Clin Infect Dis.* 2007;45(8):1019-1024.
  138. Shah DP, Shah PK, Azzi JM, Chemaly RF. Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review. *Cancer Lett.* 2016;370(2):358-364.
  139. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. *N Engl J Med.* 1997;336(13):897-904.
  140. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. *J Clin Oncol.* 2001;19(2):464-471.
  141. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. *Blood.* 2009;113(5):1175-1183.
  142. Bilmon IA, Ashton LJ, Le Marsney RE, et al. Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study. *Bone Marrow Transplant.* 2014;49(5):691-698.
  143. Inamoto Y, Shah NN, Savani BN, et al. Secondary solid cancer screening following hematopoietic cell transplantation. *Bone Marrow Transplant.* 2015;50(8):1013-1023.
  144. Ehrhardt MJ, Brazauskas R, He W, Rizzo JD, Shaw BE. Survival of patients who develop solid tumors following hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2016;51(1):83-88.
  145. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. *J Natl Cancer Inst.* 2003;95(23):1772-1783.
  146. Savani BN, Stratton P, Shenoy A, Kozanas E, Goodman S, Barrett AJ. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation--implications for screening and HPV vaccination. *Biol Blood Marrow Transplant.* 2008;14(9):1072-1075.
  147. Tedeschi SK, Savani BN, Jagasia M, et al. Time to consider HPV vaccination after allogeneic stem cell transplantation. *Biol Blood Marrow Transplant.* 2010;16(8):1033-1036.
  148. Bevans M, El-Jawahri A, Tierney DK, et al. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Patient-Centered Outcomes Working Group Report. *Biol Blood Marrow Transplant.* 2016 Sep 19. [Epub ahead of print]
  149. Rusiewicz A, DuHamel KN, Burkhalter J, et al. Psychological distress in long-term survivors of hematopoietic stem cell transplantation. *Psychooncology.* 2008;17(4):329-337.
  150. El-Jawahri AR, Vandusen HB, Traeger LN, et al. Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation. *Cancer.* 2016;122(5):806-812.
  151. Andrykowski MA, Altmaier EM, Barnett RL, Burish TG, Gingrich R, Henslee-Downey PJ. Cognitive dysfunction in adult survivors of allogeneic marrow transplantation: relationship to dose of total body irradiation. *Bone Marrow Transplant.* 1990;6(4):269-276.
  152. Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. *J Clin Oncol.* 2004;22(11):2233-2239.
  153. Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. *Clin Neuropsychol.* 2006;20(1):76-89.
  154. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. *Nat Rev Cancer.* 2007;7(3):192-201.
  155. Syrjala KL, Artherholt SB, Kurland BF, et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. *J Clin Oncol.* 2011;29(17):2397-2404.
  156. Gehring K, Sitskoorn MM, Gundy CM, et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. *J Clin Oncol.* 2009;27(22):3712-3722.
  157. Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. *J Clin Oncol.* 1998;16(7):2522-2527.
  158. Lundorff LE, Jonsson BH, Sjogren P. Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. *Palliat Med.* 2009;23(8):731-738.
  159. Meacham LR, Chow EJ, Ness KK, et al. Cardiovascular risk factors in adult survivors of pediatric cancer--a report from the childhood cancer survivor study. *Cancer Epidemiol Biomarkers Prev.* 2010;19(1):170-181.
  160. Nakasone H, Onizuka M, Suzuki N, et al. Pre-transplant risk factors for cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation. *Bone Marrow Transplant.* 2013;48(10):1317-1323.
  161. Clavert A, Peric Z, Brissot E, et al. Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* 2017;23(1):140-146.
  162. Scott BL, Pasquini M, Logan B, et al. Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. *Blood.* 2015;126(23): (Abstract LBA-128).
  163. Visentin S, Auquier P, Bertrand Y, et al. The Impact of Donor Type on Long-Term Health Status and Quality of Life after Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Leukemia: A Leucemie de l'Enfant et de L'Adolescent Study. *Biol Blood Marrow Transplant.* 2016;22(11): 2003-2010.
  164. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2006;12(2):138-151.
  165. Armenian SH, Chemaityly W, Chen M, et al. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report. *Biol Blood Marrow Transplant.* 2016;23(2):201-210
  166. Gea-Banacloche J, Komanduri K, Carpenter P, et al. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. *Biol Blood Marrow Transplant.* 2016 Oct 14. [Epub ahead of print]
  167. Hashmi SK, Bredeson C, Duarte RF, et al. National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report. *Biol Blood Marrow Transplant in press.* 2016 Oct 3. [Epub ahead of print]
  168. Morton LM, Saber W, Baker KS, et al. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Consensus Recommendations for Subsequent Neoplasms. *Biol Blood Marrow Transplant.* 2016 Sep 12. [Epub ahead of print]
  169. Shaw BE, Hahn T, Martin PJ, et al. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. *Biol Blood Marrow Transplant.* 2017;23(1):10-23.
  170. Bishop MM, Lee SJ, Beaumont JL, et al. The preventive health behaviors of long-term survivors of cancer and hematopoietic stem cell transplantation compared with matched controls. *Biol Blood Marrow Transplant.* 2010;16(2):207-214.
  171. Khera N, Chow EJ, Leisenring WM, et al. Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors. *Biol Blood Marrow Transplant.* 2011;17(7):995-1003.